KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Other Non-Current Assets (2020 - 2025)

Historic Other Non-Current Assets for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $14.7 million.

  • Recursion Pharmaceuticals' Other Non-Current Assets rose 12116.46% to $14.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.7 million, marking a year-over-year increase of 12116.46%. This contributed to the annual value of $8.8 million for FY2024, which is 3312.72% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Other Non-Current Assets stood at $14.7 million for Q3 2025, which was up 12116.46% from $9.4 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Other Non-Current Assets ranged from a high of $14.8 million in Q1 2025 and a low of $35000.0 during Q3 2021
  • Over the past 5 years, Recursion Pharmaceuticals' median Other Non-Current Assets value was $7.9 million (recorded in 2022), while the average stood at $7.5 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first soared by 2319714.29% in 2022, then plummeted by 1630.05% in 2023.
  • Recursion Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $8.7 million in 2021, then fell by 8.77% to $7.9 million in 2022, then fell by 16.3% to $6.6 million in 2023, then soared by 33.13% to $8.8 million in 2024, then soared by 66.13% to $14.7 million in 2025.
  • Its Other Non-Current Assets stands at $14.7 million for Q3 2025, versus $9.4 million for Q2 2025 and $14.8 million for Q1 2025.